InsidersTradesSigma
Track the ProtoKinetix, Inc. share price and the full insider trade history of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, ProtoKinetix, Inc. has published 22 public disclosures. Market capitalisation: €2.5m. The latest transaction was reported on 27 September 2024 (Acquisition). Among the most active insiders: SMITH CLARENCE EDWARD. All data is accessible without an account.
22
Insider Decl.
n/a
Thresholds
€697,775
19 ops.
Buy Volume
n/a
n/a
Sell Volume
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 27 September 2024
Declarations22 total
2,000,000 shares@ US$0.012.4% of flowCommon StockSEC:0001553350-24-000121:0
Canonical exit: 25 Dec 2024 (T+90)
3,400,000 shares@ US$0.014.2% of flowCommon StockSEC:0001079973-24-000893:0
Canonical exit: 11 Sept 2024 (T+90)
666,667 shares@ US$0.0151.2% of flowCommon StockSEC:0001079973-24-000553:0
Canonical exit: 18 Jun 2024 (T+90)
7,333,334 shares@ US$0.01513.3% of flowCommon StockSEC:0001079973-23-001824:0
Canonical exit: 25 Mar 2024 (T+90)
20,000 shares@ US$0.01650.5% of flowCommon StockSEC:0001079973-23-001496:0
Canonical exit: 24 Jan 2024 (T+90)
1,500,000 shares@ US$0.023.7% of flowCommon StockSEC:0001079973-23-001222:0
Canonical exit: 27 Nov 2023 (T+90)
2,000,000 shares@ US$0.024.9% of flowCommon StockSEC:0001079973-23-000894:0
Canonical exit: 13 Sept 2023 (T+90)
3,750,000 shares@ US$0.029.3% of flowCommon StockSEC:0001079973-23-000780:0
Canonical exit: 20 Aug 2023 (T+90)
2,000,000 shares@ US$0.024.9% of flowCommon StockSEC:0001079973-23-000147:0
Canonical exit: 23 Apr 2023 (T+90)
94,089 shares@ US$0.0240.3% of flowCommon StockSEC:0001079973-23-000013:0
Canonical exit: 14 Mar 2023 (T+90)
1,125,600 shares0Common StockSEC:0001079973-22-001557:0
2,520,000 shares@ US$0.0258.0% of flowCommon StockSEC:0001079973-22-001530:0
Canonical exit: 8 Mar 2023 (T+90)
3,333,333 shares@ US$0.0313.6% of flowCommon StockSEC:0001079973-22-001315:0
Canonical exit: 28 Dec 2022 (T+90)
2,666,667 shares@ US$0.0310.6% of flowCommon StockSEC:0001079973-22-000845:0
Canonical exit: 9 Oct 2022 (T+90)
10,000 shares@ US$0.0490.022% mcap0.7% of flowCommon StockSEC:0001079973-22-000596:0
Canonical exit: 14 Aug 2022 (T+90)
600,000 shares@ US$0.051.27% mcap15.2% of flowCommon StockSEC:0001079973-22-000418:0
Canonical exit: 28 Jun 2022 (T+90)
1,000,000 shares@ US$0.052.13% mcap25.5% of flowCommon StockSEC:0001079973-22-000314:0
Canonical exit: 16 Jun 2022 (T+90)
833,333 shares@ US$0.062.09% mcap25.0% of flowCommon StockSEC:0001079973-21-001272:0
Canonical exit: 22 Mar 2022 (T+90)
2,500 shares@ US$0.110.7% of flowCommon StockSEC:0001079973-21-000883:0
Canonical exit: 17 Nov 2021 (T+90)
142,857 shares@ US$0.071.2% of flowCommon StockSEC:0001079973-21-000713:0
Canonical exit: 12 Apr 2021 (T+90)
555,556 shares@ US$0.0797.0% of flowCommon StockSEC:0001079973-21-000564:0
2,000,000 sharesCommonSEC:0001140361-16-046354:0
22 of 22 declarations
关于 ProtoKinetix, Inc.
ProtoKinetix, Inc.（股票代码：PKTX）是一家在美国上市的生物技术公司，目前在OTC市场报价，而非纽约证券交易所/纳斯达克。其运营足迹在美国，在俄亥俄州设有公开的商业地址，包括道尔顿和马里埃塔。公司企业根源可追溯到1999年，当时注册为RJV Network, Inc.；2003年采用ProtoKinetix名称，此后围绕一个单一科学平台重新定位：AAGP®，一种获得专利的抗衰老/抗冻糖肽，旨在支持细胞在压力下的存活。 从分析师的角度来看，ProtoKinetix最好被描述为一家研发阶段的生物技术和知识产权公司，而非商业药物制造商。其核心工作集中于开发AAGP®在眼科、皮肤科、移植支持、再生医学和选定生物制造用例中的应用。因此，公司的商业模式高度依赖于科学验证、合作伙伴兴趣以及将临床前或早期研究转化为商业可行产品的能力。这创造了一个经典的利基生物技术公司形象：可能具有差异化技术，但伴随着重大的执行风险、资金依赖和漫长的开发周期。 ProtoKinetix将AAGP®定位为其主要资产，并在其公司网站上反复强调实验室测试、毒性研究和细胞存活研究。该分子被描述为一种小而稳定的化合物，其灵感来源于与在极端寒冷中存活的动物相关的天然生物机制。公司发布的材料表明，它已推行该平台多年，并与研究人员和顾问合作以拓宽潜在应用。然而，投资者应注意，公司的公开披露仍将其描述为一家开发阶段的企业，这意味着目前没有广泛的商业产品收入基础来支持估值。 近期公司新闻在治理方面也值得关注。2025年11月，ProtoKinetix宣布总裁兼首席执行官Clarence E. Smith去世，并任命Michael Guzzetta为继任者，同时继续担任首席财务官、秘书和司库。就市场背景而言，PKTX目前并非纽约证券交易所/纳斯达克上市公司，这在评估流动性、披露深度和机构可见性时非常重要。总的来说，ProtoKinetix是一个围绕专利细胞存活分子构建的投机性微型生物技术故事，具有悠久的运营历史、专注的知识产权平台和仍处于早期且由合作伙伴驱动的开发管线。
